Real-World Treatment Patterns for Golimumab and Concomitant Medications in Japanese Rheumatoid Arthritis Patients

Abstract

Janssen Pharmaceutical K.K. and Mitsubishi Tanabe Pharma Corporation.

Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of post-marketing surveillance data

“…In the present study, concomitant use of oral corticosteroids was associated with a lower response to GLM at 24 weeks. Our previous analysis of this PMS dataset demonstrated that disease activity was higher in patients who were using concomitant oral corticosteroids [19]. Therefore, concomitant use of oral corticosteroids is more likely to be a consequence rather than a cause of failure to control disease activity with GLM.…”

“…In the previous GO-AFTER trial, among patients who discontinued prior anti-TNF therapy, those who received GLM at 100 mg appeared to show a numerically higher response than those who received GLM at 50 mg [7]. Additionally, our previous post-hoc analysis of PMS data suggested that physicians are more likely to select 100 mg of GLM for patients who failed previous bDMARD therapy in real-world daily practice [19]. However, there has been no evidence as to the effectiveness of GLM at 100 mg compared with 50 mg in RA patients stratified by the number of previous biologic agents.…”

Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-

“…As for the effectiveness of bDMARDs in elderly patients, ABT was well tolerated and similarly efficacious in both of the non-elderly (<65 years) and elderly (≥65 years) RA patients [25]. In addition, from the post hoc analysis of post-marketing surveillance in Japan, GLM showed comparable improvement of disease activity between younger (<75 years) and elderly (≥75 years) patients [26].…”

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

“…In the GO-FORTH study, 9 out of 86 subjects who initiated GLM at a dose of 50 mg underwent dose escalation to 100 mg as rescue treatment because of lack of efficacy, resulting in subsequent improvement of the signs and symptoms of RA [4]. In real-world daily practice, dose escalation of GLM seems to achieve better control in RA patients with higher disease activity [9]. However, dose escalation of biologic agents needs to be carefully appraised since this approach can lead to higher medical costs [10] that impose a greater burden on the healthcare system.…”